MX2021009275A - Moleculas de union especificas. - Google Patents
Moleculas de union especificas.Info
- Publication number
- MX2021009275A MX2021009275A MX2021009275A MX2021009275A MX2021009275A MX 2021009275 A MX2021009275 A MX 2021009275A MX 2021009275 A MX2021009275 A MX 2021009275A MX 2021009275 A MX2021009275 A MX 2021009275A MX 2021009275 A MX2021009275 A MX 2021009275A
- Authority
- MX
- Mexico
- Prior art keywords
- specific binding
- binding molecules
- fragments
- bind
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Una molécula de unión específica que se une a CD3 y comprende un polipéptido que tiene un dominio VL de inmunoglobulina y un dominio VH de inmunoglobulina en donde el dominio VL comprende Regiones determinantes de complementariedad (CDRS) VLCDR1, VLCDR2 y VLCDR3, y en donde el dominio VH comprende Regiones Determinantes de Complementariedad (CDRs) VHCDR1, VHCDR2, VHCDR3, cada una con una secuencia de aminoácidos respectiva de la siguiente manera en donde: VLCDR1 es QDIRNY VLCDR2 es YTS VLCDR3 es QQGNTLPWT VHCDR1 es GYSFTGYA VHCDR2 es INPYKGVS VHCDR3 es ARSGYYGDSDWYFDV o una secuencia de aminoácidos idéntica al menos en un 70% a las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1901305.1A GB201901305D0 (en) | 2019-01-30 | 2019-01-30 | Specific binding molecules |
PCT/EP2020/052315 WO2020157210A1 (en) | 2019-01-30 | 2020-01-30 | Cd3-specific binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009275A true MX2021009275A (es) | 2021-08-16 |
Family
ID=65997940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009275A MX2021009275A (es) | 2019-01-30 | 2020-01-30 | Moleculas de union especificas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220119527A1 (es) |
EP (1) | EP3917959A1 (es) |
JP (1) | JP7530904B2 (es) |
KR (1) | KR20210121141A (es) |
CN (1) | CN113728005A (es) |
AU (1) | AU2020215776A1 (es) |
BR (1) | BR112021014963A2 (es) |
CA (1) | CA3127144A1 (es) |
GB (1) | GB201901305D0 (es) |
IL (1) | IL284926A (es) |
MX (1) | MX2021009275A (es) |
WO (1) | WO2020157210A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药(杭州)有限公司 | 一种接近天然分子的多肽融合分子 |
AU2023222190A1 (en) | 2022-02-20 | 2024-08-29 | Immunocore Limited | Hiv-specific binding molecules and tcr |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024146936A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a piwil1 peptide-hla complex |
WO2024146951A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US36676A (en) | 1862-10-14 | Improvement in grain-cleaners | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
AU7757581A (en) | 1980-11-19 | 1982-05-27 | United Energy Technologies Inc. | Enhanced surface tubing |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
JPS5855530Y2 (ja) | 1981-06-15 | 1983-12-20 | 松下電工株式会社 | 照明器具を有する天井 |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3464682D1 (en) | 1983-05-09 | 1987-08-13 | Gen Electric Co Plc | Cathode ray tube display device |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
EP0977886A4 (en) | 1997-03-07 | 2002-10-23 | Sunol Molecular Corp | FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR |
ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
EP1259601A2 (en) | 2000-02-22 | 2002-11-27 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
CA2457652C (en) | 2001-08-31 | 2012-08-07 | Avidex Limited | Soluble t cell receptor |
JP4436319B2 (ja) | 2002-10-09 | 2010-03-24 | メディジーン リミテッド | 単鎖組換えt細胞レセプター |
WO2006000830A2 (en) | 2004-06-29 | 2006-01-05 | Avidex Ltd | Cells expressing a modified t cell receptor |
GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
DK3736292T3 (da) * | 2013-12-17 | 2024-07-22 | Genentech Inc | Anti-CD3-antistoffer og fremgangsmåder til anvendelse |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
ES2914648T3 (es) | 2016-04-08 | 2022-06-15 | Immunocore Ltd | Receptores de células T |
GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
-
2019
- 2019-01-30 GB GBGB1901305.1A patent/GB201901305D0/en not_active Ceased
-
2020
- 2020-01-30 BR BR112021014963-5A patent/BR112021014963A2/pt unknown
- 2020-01-30 EP EP20703192.3A patent/EP3917959A1/en active Pending
- 2020-01-30 CA CA3127144A patent/CA3127144A1/en active Pending
- 2020-01-30 KR KR1020217027112A patent/KR20210121141A/ko unknown
- 2020-01-30 MX MX2021009275A patent/MX2021009275A/es unknown
- 2020-01-30 US US17/427,592 patent/US20220119527A1/en active Pending
- 2020-01-30 JP JP2021544406A patent/JP7530904B2/ja active Active
- 2020-01-30 AU AU2020215776A patent/AU2020215776A1/en active Pending
- 2020-01-30 CN CN202080012045.4A patent/CN113728005A/zh active Pending
- 2020-01-30 WO PCT/EP2020/052315 patent/WO2020157210A1/en active Application Filing
-
2021
- 2021-07-18 IL IL284926A patent/IL284926A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3127144A1 (en) | 2020-08-06 |
GB201901305D0 (en) | 2019-03-20 |
JP2022523507A (ja) | 2022-04-25 |
CN113728005A (zh) | 2021-11-30 |
EP3917959A1 (en) | 2021-12-08 |
IL284926A (en) | 2021-09-30 |
KR20210121141A (ko) | 2021-10-07 |
US20220119527A1 (en) | 2022-04-21 |
JP7530904B2 (ja) | 2024-08-08 |
AU2020215776A1 (en) | 2021-09-09 |
WO2020157210A1 (en) | 2020-08-06 |
BR112021014963A2 (pt) | 2021-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019224718A3 (en) | Psma binding agents and uses thereof | |
MX2021009275A (es) | Moleculas de union especificas. | |
ZA201901066B (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
PH12018500482A1 (en) | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies | |
PH12020551920A1 (en) | Anti-cd3 antibodies and uses thereof | |
CR20200171A (es) | Contorsbodies 2 + 1 biespecíficos | |
MX2022014463A (es) | Construcciones de union a antigeno para moleculas diana. | |
MX2020010382A (es) | Anticuerpos biespecificos para pd1 y tim3. | |
MY186352A (en) | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies | |
PH12019502087A1 (en) | Anti-par2 antibodies and uses thereof | |
GEP20217220B (en) | Pd1 and/or lag3 binders | |
WO2013188693A8 (en) | Antigen binding constructs to cd3 | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
EP4065164A4 (en) | ANTIBODIES AGAINST CD3 AND BCMA AND BISPECIFIC BINDING PROTEINS PRODUCED THEREOF | |
MX2021008216A (es) | Anticuerpos anti-tigit. | |
EP4414034A3 (en) | Antibodies specific for cd3 and uses thereof | |
MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
WO2018227063A8 (en) | Anti-robo2 antibodies, compositions, methods and uses thereof | |
WO2021041300A3 (en) | Bispecific antibodies and uses thereof | |
MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2022001882A (es) | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. | |
MX2021015882A (es) | Fragmentos de unión a antígeno egfr y composiciones que los comprenden. | |
MX2021000305A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000288A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. |